Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DREAM: Switching from DTG/3TC/ABC to Genvoya for Neurotoxicity in HIV
NCT03067285Phase 4Completed
- Sponsor
- Fundación SEIMC-GeSIDA
- Start
- Sep 2017
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of tenofovir alafenamide in human immunodeficiency virus infection (HIV), sponsored by Fundación SEIMC-GeSIDA. Started Sep 2017; status: completed.
02
Drugs
tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03067285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03067285.